Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combining selinexor with alisertib to target the p53 pathway in neuroblastoma

22 Feb 2022

Abstract excerpt

Neuroblastoma accounts for 15% of cancer-related deaths in children, highlighting an unmet need for novel therapies. Selinexor is a small molecule inhibitor of XPO1. XPO1 shuffles cargo proteins with a nuclear export sequence from the nucleus to the cytosol, many of which are essential for cancer growth and cell maintenance. We systematically tested the effect of selinexor against neuroblastoma cells in vitro and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Neuroblastoma Research and Treatments
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35217309
DOI: 10.1016/j.neo.2022.100776

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combining selinexor with alisertib to target the p53 pathway in neuroblastomaPMID 35217309Read ↗

E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1Semantic proximity Read ↗

Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.Semantic proximity Read ↗

Aurora Kinases as Targets in Drug-Resistant Neuroblastoma CellsSemantic proximity Read ↗

Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastomaSemantic proximity Read ↗

Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastomaSemantic proximity Read ↗

Targeting the p53 pathway to treat Malignant Rhabdoid and Atypical Teratoid Rhabdoid TumorsSemantic proximity Read ↗

MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.Semantic proximity Read ↗

Multiple components of the spliceosome regulate Mcl1 activity in neuroblastomaSemantic proximity Read ↗

Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degradersSemantic proximity Read ↗

Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosisSemantic proximity Read ↗

Cell Survival Signaling in NeuroblastomaSemantic proximity Read ↗

SAPCD2 promotes neuroblastoma progression by altering the subcellular distribution of E2F7Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.